Capsid Tropism Screening Platforms Global Market Report 2026

The capsid tropism screening platforms market size has grown rapidly in recent years. It will grow from $0.74 billion in 2025 to $0.85 billion in 2026 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to increasing investment in gene therapy research, growing demand for viral vector optimization, adoption of flow cytometry and sequencing technologies, rising focus on personalized medicine, expansion of pharmaceutical and biotech R&D infrastructure.

The capsid tropism screening platforms market size is expected to see rapid growth in the next few years. It will grow to $1.45 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to growing use of AI-driven capsid tropism analysis, increasing deployment of high-content imaging and microfluidics, rising demand for single-cell sequencing and advanced screening platforms, expansion of contract research organizations (CROs), increasing integration of multiplex assay and digital PCR technologies. Major trends in the forecast period include increasing adoption of high-throughput screening platforms, rising demand for next-generation sequencing solutions, growing integration of flow cytometry technologies, expansion of assay kits and reagent offerings, rising focus on gene therapy and vaccine development applications.

The growing demand for targeted gene therapies is projected to drive the expansion of the capsid tropism screening platforms market during the forecast period. Targeted gene therapies involve delivering therapeutic genetic material to specific cells or tissues to correct, modify, or replace defective genes responsible for disease. The surge in demand for these therapies is influenced by several factors, including the rising incidence of genetic and rare diseases, advancements in vector engineering technologies, and increased investment in precision medicine approaches designed to enhance treatment effectiveness while minimizing off-target effects. Capsid tropism screening platforms are vital in gene therapy development, enabling systematic evaluation and selection of viral vectors with optimal tissue and cell specificity. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based gene and cell therapy organization, the number of gene therapies in Phase III clinical trials rose by 10% in Q4 2023, marking the first quarterly increase since Q3 2022. Therefore, the increasing demand for targeted gene therapies is driving the growth of the capsid tropism screening platforms market.

Key companies operating in the capsid tropism screening platforms market are forming strategic partnerships to develop innovative high-throughput and barcoded adeno-associated virus screening solutions. Strategic partnerships propel the growth of the capsid tropism screening platforms market by enabling collaborative development of advanced adeno-associated virus screening technologies, expanding product portfolios, and accelerating gene therapy research and commercialization. For example, in August 2025, PackGene Biotech Inc., a US-based biotechnology company, entered a strategic licensing agreement with the Children’s Medical Research Institute (CMRI), an Australia-based independent organization, to commercialize barcoded high-throughput adeno-associated virus capsid screening kits. These kits allow researchers to rapidly evaluate multiple adeno-associated virus capsid variants simultaneously using a barcode system and next-generation sequencing. The collaboration aims to accelerate gene therapy development by streamlining capsid selection and improving access to advanced screening tools.

In April 2023, Ginkgo Bioworks Holdings Inc., a US-based synthetic biology platform company, acquired adeno-associated virus capsid discovery and engineering platform assets from StrideBio for an undisclosed amount. Through this acquisition, Ginkgo Bioworks aims to advance its technological capabilities in viral vector design and capsid tropism screening, reinforcing its position in the gene therapy market. StrideBio Inc. is a US-based provider of advanced adeno-associated virus capsid discovery and engineering technologies that enable optimized tissue-specific delivery for gene therapies.

Major companies operating in the capsid tropism screening platforms market are Sarepta Therapeutics Inc., Voyager Therapeutics Inc., Bluebird Bio Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., MeiraGTx Holdings plc, Dyno Therapeutics Inc., 4D Molecular Therapeutics Inc., Asklepios BioPharmaceutical Inc., PackGene Biotech Inc., Creative Biolabs Inc., VectorBuilder Inc., uniQure N.V., Homology Medicines Inc., Capsida Biotherapeutics Inc., LogicBio Therapeutics Inc., Capsigen Inc., GeneMedi Inc., Spark Therapeutics Inc., Creative Biogene Inc.

North America was the largest region in the capsid tropism screening platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the capsid tropism screening platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the capsid tropism screening platforms market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The capsid tropism screening platforms market consists of revenues earned by entities by providing services such as tissue-specific tropism analysis, high-throughput viral vector profiling, preclinical vector optimization studies, custom assay development for capsid targeting, and cell type-specific transduction efficiency testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The capsid tropism screening platforms market also includes sales of high-throughput screening kits, reporter assays, cell panels, bioinformatics tools, and next-generation sequencing (ngs) kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Capsid tropism screening platforms are specialized technologies used to evaluate and identify the specific tissue or cell types that viral capsids can effectively target and enter. These platforms allow researchers to optimize viral vectors for gene therapy by assessing delivery efficiency, specificity, and safety across various biological environments.

The key technologies of capsid tropism screening platforms include high-throughput screening, next-generation sequencing, flow cytometry, and other technologies. High-throughput screening refers to advanced methods for rapid evaluation of capsid variants for tissue targeting efficiency and specificity. Product types include assay kits, reagents, instruments, software, and services. Applications include gene therapy development, vaccine development, drug discovery, and other areas, serving pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and other end-users.

Tariffs on imported reagents, instruments, and high-throughput screening components are affecting the capsid tropism screening platforms market by increasing procurement and operational costs, particularly impacting assay kits, sequencing instruments, and flow cytometry devices. Regions such as North America, Europe, and Asia-Pacific that rely heavily on imported biotech instruments are most affected. While tariffs raise costs, they also encourage domestic manufacturing, support local biotech innovation, and drive the development of cost-efficient, regionally produced reagents and instruments, fostering long-term resilience and supply chain stability.

The capsid tropism screening platforms market research report is one of a series of new reports that provides capsid tropism screening platforms market statistics, including capsid tropism screening platforms industry global market size, regional shares, competitors with a capsid tropism screening platforms market share, detailed capsid tropism screening platforms market segments, market trends and opportunities, and any further data you may need to thrive in the capsid tropism screening platforms industry. This capsid tropism screening platforms market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.